Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bristol-Myers Squibb Company is conducting an important clinical study titled A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors. The study aims to evaluate the safety, tolerability, and anti-cancer activity of the experimental drug BMS-986488, both alone and in combination with other treatments, in patients with advanced malignant tumors.
The interventions being tested include BMS-986488 as a monotherapy and in combination with other drugs such as Adagrasib, Cetuximab, and Nivolumab. These combinations are designed to enhance the treatment’s effectiveness against cancer.
This is an interventional study with a non-randomized, sequential design. There is no masking involved, meaning both researchers and participants know which treatments are being administered. The primary purpose of the study is treatment-focused.
The study began on March 25, 2025, with updates last submitted on June 24, 2025. These dates are crucial as they mark the progress and current status of the study, which is still recruiting participants.
The outcome of this study could significantly impact Bristol-Myers Squibb’s stock performance and investor sentiment, especially if the results demonstrate strong efficacy and safety. This could also influence the competitive landscape in the oncology sector, where other companies are developing similar treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.